Antares Pharma, Inc. provided revenue guidance for the year 2022. For the year, the company expects revenue to be range of $200 to $220 million, which does not include any unapproved products and assumes no significant disruptions to supply or operations due to the ongoing COVID-19 pandemic. Excluding 2021 OTREXUP® proprietary revenue, the guidance range represents a 18% to 30% year-over-year growth rate.
Antares Pharma, Inc.
Equities
ATRS
US0366421065
Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | |
---|---|---|
-5.56% | 181B | |
-0.11% | 108B | |
-6.17% | 66.12B | |
+2.64% | 50.65B | |
+6.58% | 43.11B | |
+3.40% | 41.3B | |
+21.98% | 31.6B | |
+16.81% | 25.03B | |
-5.81% | 24.16B |